3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
279
Carboplatin
214
Cisplatin
145
Gemcitabine
144
Paclitaxel
142
Bevacizumab
115
Pemetrexed
112
Docetaxel
100
Oxaliplatin
78
Dexamethasone
77
durvalumab
76
Fluorouracil
76
atezolizumab
75
Nivolumab
74
Cyclophosphamide
74
130-nm albumin-bound paclitaxel
71
Fulvestrant
68
Cetuximab
63
Capecitabine
63
Injections
61
Leucovorin
60
Rituximab
55
fludarabine
50
Lenalidomide
49
venetoclax
43
Prednisone
43
Irinotecan
42
enzalutamide
39
Letrozole
39
tislelizumab
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled